Comparison of 25-hydroxyvitamin D levels in breast cancer patients and control group: a cross-sectional study


  • Adrienne Prati Lucarelli
  • Maria Marta Martins



vitamin D, breast neoplasms, calcitriol, carcinogenesis, metabolism


To assess serum vitamin D levels in patients with breast cancer and compare them against control patients without the disease, testing the hypothesis that patients with breast cancer have lower serum levels of the hormone than patients without the cancer. A total of 101 treatment-naïve patients diagnosed with breast cancer at the Mastology Outpatient Clinic of the Department of Obstetrics and Gynecology of the Irmandade da Santa Casa de São Paulo (ISCMSP), and 100 control patients without the disease at the Endocrinologic Gynecology Outpatient Clinic of the same institution were selected. Serum vitamin D levels for the two groups were compared. Mean serum vitamin D level was 23.85 ng/dL in the breast cancer group versus 28.19 ng/dL in the control group, where this difference proved statistically significant on Student´s t-test (p=0.002). Patient age was a confounding bias, where no correlation between serum level and age was evident on the scatter plot. Patients with breast cancer had lower serum Vitamin D levels than patients without the cancer. However, longitudinal studies should be conducted to determine whether a causal relationship exists between these variables.


Vanhevel J, Verlinden L, Doms S, Wildiers H, Verstuyf A. The role of vitamin D in breast cancer risk and progression. Endocr Relat Cancer. 2022 Jan 24;29(2):R33-R55. doi: 10.1530/ERC-21-0182

Voutsadakis IA. Vitamin D baseline levels at diagnosis of breast cancer: A systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2021 Mar;14(1):16-26. doi: 10.1016/j.hemonc.2020.08.005

Kabat GC, Kim MY, Lee JS, Ho GY, Going SB, Beebe-Dimmer J, Manson JE, Chlebowski RT, Rohan TE. Metabolic Obesity Phenotypes and Risk of Breast Cancer in Postmenopausal Women. .Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1730-1735. doi: 10.1158/1055-9965.EPI-17-0495. Epub 2017 Sep 22.PMID: 28939589

Shahrzad MK, Gharehgozlou R, Fadaei S, Hajian P, Mirzaei HR. Vitamin D and Non-coding RNAs: New Insights into the Regulation of Breast Cancer.

Curr Mol Med. 2021;21(3):194-210. doi: 10.2174/1566524020666200712182137

O'Brien KM, Sandler DP, Xu Z, Kinyamu HK, Taylor JA, Weinberg CR. Vitamin D, DNA methylation, and breast cancer. .Breast Cancer Res. 2018 Jul 11;20(1):70. doi: 10.1186/s13058-018-0994-y

Welsh J. Vitamin D and breast cancer: Past and present. .J Steroid Biochem Mol Biol. 2018 Mar;177:15-20. doi: 10.1016/j.jsbmb.2017.07.025. Epub 2017 Jul 23.PMID: 28746837

Blasiak J, Pawlowska E, Chojnacki J, Szczepanska J, Fila M, Chojnacki C. Vitamin D in Triple-Negative and BRCA1-Deficient Breast Cancer-Implications for Pathogenesis and Therapy. .Int J Mol Sci. 2020 May 23;21(10):3670. doi: 10.3390/ijms21103670

O'Brien KM, Keil AP, Harmon QE, Jackson CL, White AJ, Díaz-Santana MV, Taylor JA, Sandler DP. Vitamin D Supplement Use and Risk of Breast Cancer by Race-Ethnicity. Epidemiology. 2022 Jan 1;33(1):37-47. doi: 10.1097/EDE.0000000000001413

Estébanez N, Gómez-Acebo I, Palazuelos C, Llorca J, Dierssen-Sotos T Vitamin D exposure and Risk of Breast Cancer: a meta-analysis. Sci Rep. 2018 Jun 13;8(1):9039. doi: 10.1038/s41598-018-27297-1




How to Cite

Lucarelli, A. P., & Martins, M. M. (2023). Comparison of 25-hydroxyvitamin D levels in breast cancer patients and control group: a cross-sectional study. Brazilian Journal of Health Review, 6(6), 28465–28472.



Original Papers